The encyclopedia · Software & IT · Strategic decision · 2000–2021
M3 built a doctor portal that is free for physicians and paid for by pharma
M3's m3.com gives doctors free medical information and charges pharma for reaching them through MR-kun, a model that produced 34% operating margins.
M3 (エムスリー)
the move
Pharmaceutical reps (MRs) historically visited hospitals in person to hand drug information to busy doctors, wasting huge amounts of waiting time for a few minutes of conversation. M3, founded in 2000, moved that interaction online: m3.com became a portal for doctors, and the MR-kun service let pharma firms send product information to member doctors through the site.
The economics are deliberately one-sided: pharma companies pay M3 usage fees, while doctors receive the information for free. That produced an estimated 30 billion yen in annual revenue from around 70 pharma firms, at a reported 34% operating margin, and made MR-kun so embedded that 'no pharma employee doesn't know MR-kun'.
The doctor base is the moat: m3.com plus overseas medical sites acquired through M&A gave M3 roughly half the world's doctors as members. When the pandemic froze face-to-face MR visits, MR-kun orders grew more than 2.5 times year-on-year in April-September 2020, and M3 nearly doubled its sales team to capture the shift.
why it works
- Free access wins the scarce asset — doctors' attention and registration.
- Pharma pays for measurable reach instead of costly in-person visits.
- The membership base compounds: more doctors attract more pharma budget.
- Platform economics delivered a 34% operating margin at scale.
what transfers
When one side has scarce attention (doctors) and the other has budget (pharma), make the scarce side free and let the funded side pay for access — the classic two-sided platform inversion.
what came after
COVID made online medical information delivery the default, and M3's order intake more than doubled in the first half of FY2020. By 2021 M3 ranked among Japan's top-20 companies by market capitalization, later combining its doctor platform with LINE for online consultation services.
references
spotted an error? The archive wants to know.